We are Committed to being a Collaborative Platform for Innovative Biotech Companies from around the World.
Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.
An Innovative Idea is All You Need
Our leading CRO platform is productive and efficient and it enables both quick and quality drug candidate discovery
Average time to invest: 2 months; Introductions for later-stage funding and financial advice
Business Partners Venture Advisors
Assistance in procuring internal or external resources
“Back-office” support (HR, Accounting, Procurement, BD, Financing, etc.)
We invest in some of the most innovative founders to build a unique portfolio covering a wide range of indications and drug types.
Read the most up to date information about us and our partners.
To jointly work on the development of autoimmune diseases therapies
It is expected that the phase I clinical dose-climbing trial will be completed in about three months.
To Jointly Accelerate the Early Drug Discovery through AI Technology
The cradle for biotech companies from all over the world.
The funds will be mainly used to support the clinical development of innovative ophthalmic drug pipelines.
The cradle for promising biotech companies from all over the world.